The new CellaVision® Bone Marrow Aspirate Application launches in EMEA

CellaVision today announces the launch of its CellaVision® Bone Marrow Aspirate (BMA) Application across the EMEA region, extending its digital cell morphology platform into bone marrow aspirate analysis — one of the most complex areas in laboratory diagnostics.

The application received its CE marking approval as a Class C product under the European Union In Vitro Diagnostic Regulation (EU IVDR) on December 8, 2025, confirming compliance with stringent requirements for safety, performance, and quality.

Bone marrow aspirate examination remains central to diagnosing and monitoring blood cancers and other serious blood diseases. The process is typically manual, time-consuming, and highly dependent on expertise. Peter Wilson, VP Global Marketing at CellaVision highlights that "we are bringing AI-assisted digital workflows to this critical discipline, supporting laboratories in delivering more consistent and traceable results." By digitalizing key steps in bone marrow morphology, the CE-marked CellaVision BMA Application offers laboratories a solid solution for automating, standardizing, and simplifying the morphological examination of bone marrow aspirates.

CellaVision collaborates with Sysmex Corporation as distribution partner for the CellaVision BMA Application and leverages from already established relationships with hospital and reference laboratories across the region.

The CellaVision BMA Application will be introduced to the laboratory hematology community at the International Symposium on Technological Innovations in Laboratory Hematology, hosted by the International Society for Laboratory Hematology (ISLH) from April 17-19, 2026, in Edinburgh, UK.

Contact

Helena Raihle
Corporate Communications & Investor Relations
Tel: + 46 70 822 70 93
www.cellavision.com
helena.raihle@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 12 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

The new CellaVision® Bone Marrow Aspirate Application launches in EMEA